KT
Kevin Tang (Director) filed 9 Form 4 reports in the trailing twelve months (9 purchases, 0 sales), most often in Aurinia Pharmaceuticals Inc. (AUPH). Across 8 priced purchase filings, the average 21-session return was +4.8% from execution and +6.8% from disclosure (delay-adjusted; derived). The largest single filing was $12.7M of AUPH (898,400 sh across 5 lots, as filed), executed Feb 27. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+4.8%
avg across 8 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+6.8%
same 8 filings, from disclosure
Filings, ttm
9
9 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$28.0M
shares × price, as filed
Last traded
Oct 16
Filed Oct 20
Median ADV $22.3M across their filed names
Impact on $10,000 · 12M
$12,441 (+24.4%)
S&P 500 $10,907 (+9.1%) · 15.3 pts ahead
Kevin Tang
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $65.1M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
9 filings
Sector per market data · by filing · past 12 months
Most traded names
AUPHRecent filings
AUPHPURCHASE
Aurinia Pharmaceuticals Inc.
View filing →
$12.7M898,400 sh across 5 lots
Exec Feb 27
Filed Mar 3 · 5:35 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. View filing → $13.6M
1,300,000 sh across 3 lots
Exec Aug 1 2025
Filed Aug 5 2025 · 5:31 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. View filing → $12.7M
1,600,000 sh across 6 lots
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. View filing → $10.8M
1,200,000 sh across 3 lots
Exec Dec 5 2024
Filed Dec 9 2024 · 5:30 PM ET